With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
Ruth Lopert is a public health physician and independent consultant in global health, pharmaceutical policy, and health technology assessment. She is a Chercheur Associé Principal at the University of Strasbourg and holds adjunct professorial appointments at George Washington University in the Department of Clinical Research & Leadership and in the Department of Health Policy & Management, where she was a visiting professor in 2011–12 and a Harkness fellow in Health Policy in 2006–07. Ruth has worked in more than 15 countries on assignments for the World Bank, the Inter-American Development Bank, PAHO, WHO, NICE-International, Oxford Policy Management Limited, and Management Sciences for Health, as well as directly for various national Ministries of Health.
From 2008-11 Ruth was the chief medical officer in the Australian drug and therapeutics regulatory agency, the Therapeutic Goods Administration. Previous roles include establishing and directing the pharmaceutical policy unit in the Australian Department of Health, managing the operations of the national drug coverage program, the Pharmaceutical Benefits Scheme; and as a clinical and policy advisor to the national formulary committee. Ruth is a fellow of the Faculty of Public Health of the Royal Australasian College of Physicians, a member of the Royal Society of Medicine of the UK, a foreign corresponding member of l’Académie Nationale de Pharmacie of France, and a former member of the WHO Expert Advisory Panel on Drug Policies & Management. She is the author of more than 80 refereed articles, book chapters, and monographs on drug and therapeutics regulation, public health policy, health and pharmaceutical economics and policy, health technology assessment (HTA), and issues at the intersection of trade, globalization, intellectual property, and access to medicines.